---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-020562"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2026-06-15T10:23:55+00:00"
generated_at: "2026-06-15T10:25:09.345233+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Filana shareholders approve 2018 Omnibus Incentive Plan amendment; authorized shares increased to 9M

## Summary
- Shareholders approved Amendment No. 2 to the 2018 Omnibus Incentive Plan, increasing authorized shares from 5M to 9M (4M added).
- Plan term extended through January 31, 2030; repricing of options/SARs explicitly prohibited without stockholder approval.
- Three directors elected: Richard J. Barry, Pierre Gravier, Claude Nicaise, M.D. (each ~8.9M for, ~1.5M withheld, ~14.1M broker non-votes).
- Ernst & Young ratified as auditor for FY2026 (22.7M for, 1.4M against). Non-binding say-on-pay passed (7.5M for, 2.8M against).
- 51% of outstanding shares (24.6M of 48.3M) represented at the meeting, constituting a quorum.

## SEC filing metadata
- accession: 0001437749-26-020562
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2026-06-15T10:23:55+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000143774926020562/0001437749-26-020562-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000143774926020562/sava20260610_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-020562
- JSON: https://secwatch.observer/filing/0001437749-26-020562.json
- Plain text: https://secwatch.observer/filing/0001437749-26-020562.txt

## Key facts
- Shareholder Votes
  FILANA THERAPEUTICS, INC. shareholders approved Amendment to the 2018 Omnibus Incentive Plan at the 2026-06-11 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2026-06-11
  source text: Proposal Two – An amendment to the Company’s 2018 Omnibus Incentive Plan was approved based upon the following votes: For Against Abstain Broker Non -Vote 8,427,565 1,869,290 118,621 14,144,300
  evidence_url: https://www.sec.gov/Archives/edgar/data/1069530/000143774926020562/0001437749-26-020562-index.htm
- Shareholder Votes
  FILANA THERAPEUTICS, INC. shareholders approved Election of three nominees to the Board of Directors at the 2026-06-11 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-11
  source text: Proposal One – Three (3) nominees for election or re-election to the Board of Directors were elected to serve for a three-year term, and until their successors are duly elected and qualified, based upon the following votes: Director For Withheld Broker Non-Vote Richard J. Barry 8,851,285 1,564,191 14,144,300 Pierre Gravier 9,069,595 1,345,881 14,144,300 Claude Nicaise, M.D. 8,924,355 1,491,121 14,144,300
  evidence_url: https://www.sec.gov/Archives/edgar/data/1069530/000143774926020562/0001437749-26-020562-index.htm
- Shareholder Votes
  FILANA THERAPEUTICS, INC. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm at the 2026-06-11 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-11
  source text: Proposal Three – The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026, was ratified based upon the following votes: For Against Abstain 22,671,610 1,408,513 479,653
  evidence_url: https://www.sec.gov/Archives/edgar/data/1069530/000143774926020562/0001437749-26-020562-index.htm
- Shareholder Votes
  FILANA THERAPEUTICS, INC. shareholders approved Advisory vote on executive compensation at the 2026-06-11 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-11
  source text: Proposal Four – The 2025 executive compensation for the Company’s named executive officers was approved, on a non-binding advisory vote, based upon the following votes: For Against Abstain Broker Non -Vote 7,487,142 2,827,840 100,494 14,144,300
  evidence_url: https://www.sec.gov/Archives/edgar/data/1069530/000143774926020562/0001437749-26-020562-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.